Begoña Bermejo

Universitat de València — Spain

Medicine · Health Sciences

40h-index6.5kcitations630works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(278), HER2/EGFR in Cancer Research(156), Cancer Treatment and Pharmacology(118), Breast Cancer Treatment Studies(92), Cancer Genomics and Diagnostics(91)

Publications628 total

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer
Clinical Cancer Research·2025Open Access
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.
UNC Libraries·2025Open Access
Supplementary Table S8 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S1 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S3 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S10 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Table S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S11 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Table S13 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S2 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S9 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Figure S6 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study
ESMO Open·2025· 1 citedOpen Access
Supplementary Figure S2 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
2025Open Access
Supplementary Table S7 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S12 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S10 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
page 1 of 32Next →

Frequent Co-authors

Aňa Lluch(14), Eva Ciruelos(12), Antonio Llombart‐Cussac(12), Aleix Prat(12), Javier Cortés(11), Montserrat Muñoz-Mateu(8), Paolo Nucíforo(8), Serafín Morales(8), Mafalda Oliveira(8), Marco Colleoni(7), Laia Paré(7), Noelia Martínez-Jáñez(7), Lourdes Calvo(7), María Teresa Martínez(7), Patricia Galván(6), María Vidal(6), Sònia Pernas(6), Patricia Villagrasa(6), Cristina Hernándo(6), Pîlar Eroles(6)